Chimeric Antigen Receptor-Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages S2-

  Riddell, Stanley R ^a   Jensen, Michael C ^b   June, Carl H ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CD20 ANTIBODY; DNA; IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL SURVIVAL; DNA MODIFICATION; GENE TRANSFER; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSTIMULATION; MEMORY T LYMPHOCYTE; MOLECULAR RECOGNITION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 84871881560     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.021     Document Type: Article

References (42)

1. Bacher U., Talano J.A., Bishop M.R. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant 2012, 18(1 Suppl):S62-S73.
2. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA 1993, 90:720-724.
3. Sadelain M., Riviere I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45.
4. Song D.G., Ye Q., Poussin M., et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012, 119:696-706.
5. Stephan M.T., Ponomarev V., Brentjens R.J., et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007, 13:1440-1449.
6. Brown C.E., Starr R., Aguilar B., et al. Stem-like tumor-initiating cells isolated from IL-13α2-expressing gliomas are targeted and killed by IL-13 zetakine-redirected T cells. Clin Cancer Res 2012, 18:2199-2209.
7. Cooper L.J., Topp M.S., Serrano L.M., et al. T cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B lineage leukemia effect. Blood 2003, 101:1637-1644.
8. Hudecek M., Schmitt T.M., Baskar S., et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010, 116:4532-4541.
9. Jensen M.C., Clarke P., Tan G., et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther 2000, 1:49-55.
10. Peinert S., Prince H.M., Guru P.M., et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther 2010, 17:678-686.
11. Dutour A., Marin V., Pizzitola I., et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol 2012, 2012:683065.
12. Barber A., Meehan K.R., Sentman C.L. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther 2011, 18:509-516.
13. Kowolik C.M., Topp M.S., Gonzalez S., et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006, 66:10995-11004.
14. Till B.G., Jensen M.C., Wang J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
15. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
16. June C.H. Principles of adoptive T cell cancer therapy. J Clin Invest 2007, 117:1204-1212.
17. Kershaw M.H., Teng M.W., Smyth M.J., et al. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005, 5:928-940.
18. James S.E., Greenberg P.D., Jensen M.C., et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008, 180:7028-7038.
19. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
20. Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric antigen receptor-transduced T cells. Blood 2012, 119:2709-2720.
21. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
22. Brentjens R.J., Riviere I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
23. Till B.G., Jensen M.C., Wang J., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940-3950.
24. Louis C.U., Savoldo B., Dotti G., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
25. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
26. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011, 121:1822-1826.
27. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
28. Weng N.P., Araki Y., Subedi K. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. Nat Rev Immunol 2012, 12:306-315.
29. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008, 118:294-305.
30. + T cells in immunodeficient mice. Blood 2011, 117:1888-1898.
31. Gattinoni L., Lugli E., Ji Y., et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
32. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
33. Zygmunt B., Veldhoen M. T helper cell differentiation more than just cytokines. Adv Immunol 2011, 109:159-196.
34. + T cells against NY-ESO-1. N Engl J Med 2008, 358:2698-2703.
35. Dudley M.E., Yang J.C., Sherry R., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
36. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
37. + T cells derived from virus-specific central memory T cells. Blood 2012, 119:72-82.
38. Di Stasi A., Tey S.K., Dotti G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.
39. Barrett D.M., Zhao Y., Liu X., et al. Treatment of advanced leukemia in mice with mRNA-engineered T cells. Hum Gene Ther 2011, 22:1575-1586.
40. Buchholz D.R. Tet-on binary systems for tissue-specific and inducible transgene expression. Methods Mol Biol 2012, 917:265-275.
41. Pegram H.J., Lee J.C., Hayman E.G., et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012, 119:4133-4141.
42. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.